Objective To observe lesion to hver function and reactivation of HBV in HbsAg positive nonHodgkin lymphoma patient after CHOP chemotherapy. Methods There 62 nonHodgkin lymphoma cases which were hospitalized in our hospital from 2004 to 2007 were collected including 26 HBV carriers （HBsAg-Positive group）,36 cases negative for HBV （non-HBsAg-positive group）. All patients were treated with CHOP chemotherapy, at least two cycles. The liver function was monitored before chemotherapy and at end of the third week of every cycle. Serially collected serum samples were analyzed for serum HBV DNA before chemotherapy and at end of the third week of every two cycle in HBsAg-positive group. All patients with abnormal liver function after chemothrapy were given liver pretectant. Results The percentage of patients with abnormal liver function increase significantly in HBsAg-positive group more than that of non-HBsAg-positive group afer four and six cycles of chemothrapy （P〈O.05）; In HBsAg-positive group, the percentage of patients with abnormal liver function was significantly increased after six cycles of chemothrapy higher than that of two cycles chemothrapy （P〈 0.05）. The positive percentage of serum HBVDNA afer six cycles of chemothrapy was higer than that of two cycles of chemothrapy （P 〈 0.01 ）in HBsAg-positive group. There were no dierences significantly in the positive peroentage of serum HBVDNA between six and four cycles chemothrapy （P〉0.05）. Conclusions Lesions to liver function of HBsAg-positive nonHodgkin lymphoma patients after CHOP chemotherapy may occur easily and the risk of reactivation of HBV may increase, and active precaution measueres be taken.
China Tropical Medicine